Jose Luis Pelegrino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Luis Pelegrino has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Harvey Artsob
Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada
3 shared publications- Philippe Buchy
Institut Pasteur du Laos, Ministry of Health, Vientiane P.O. Box 3560, Laos
3 shared publications Sutee Yoksan
Center for Vaccine Development, Mahidol University, Bangkok, Thailand
3 shared publicationsDuane J. Gubler
Duke–NUS Graduate Medical School Singapore, 8 College Road, 169857, Singapore
2 shared publicationsHarold S. Margolis
Division of Vector-Borne Infectious Diseases, Dengue Branch, Centers for Disease Control and Prevention, 1324 Calle Cañada, San Juan, 00920-3860, Puerto Rico
2 shared publicationsScott B. Halstead
Pediatric Dengue Vaccine Initiative, Kwanak PO Box 14, Seoul, 151-600, Korea
2 shared publications
Latest Publications
- Open Access
- 16 October 2014
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 8 (10) , e3171
Evaluation of Commercially Available Diagnostic Tests for the Detection of Dengue Virus NS1 Antigen and Anti-Dengue Virus IgM Antibody
Commercially available diagnostic test kits for detection of dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM were evaluated for their sensitivity and specificity and other performance characteristics by a diagnostic laboratory network developed by World Health Organization (WHO), the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Pediatric Dengue Vaccine Initiative (PDVI). Each network laboratory contributed characterized serum specimens for the panels used in the evaluation. Microplate enzyme-linked immunosorbent assay (ELISA) and rapid diagnostic test (RDT formats) were represented by the kits. Each ELISA was evaluated by 2 laboratories and RDTs were evaluated by at least 3 laboratories. The reference tests for IgM anti-DENV were laboratory developed assays produced by the Armed Forces Research Institute for Medical Science (AFRIMS) and the Centers for Disease Control and Prevention (CDC), and the NS1 reference test was reverse transcriptase polymerase chain reaction (RT-PCR). Results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60–75% and specificity 71–80%; NS1 RDT sensitivity was 38–71% and specificity 76–80%; the IgM anti-DENV RDTs sensitivity was 30–96%, with a specificity of 86–92%, and IgM anti-DENV ELISA sensitivity was 96–98% and specificity 78–91%. NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92-99% and the IgM anti-DENV RDTs from 88–94%. Dengue virus (DENV) infection occurs throughout tropical and sub-tropical regions of the world where dengue is a major public health problem. Laboratory diagnosis of dengue with a single serum specimen obtained during the acute phase of the illness requires tests to detect IgM antibodies to DENV or the virus genome. A previous evaluation of available tests for IgM anti-DENV showed wide variability. The present study examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable. The study found variability among the microplate ELISAs for both analytes but some tests performed with sensitivity and specificity acceptable for routine dengue diagnostics. The RDT's for both analytes had variable sensitivity that could be considered acceptable for routine clinical diagnostics. There is the need to maintain a network of dengue reference laboratories to conduct similar evaluations as additional dengue diagnostic tests become commercially available in order to guide the use for surveillance, clinical diagnosis and research.
- 16 October 2014
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 8 (10) , e3171
Open AccessEvaluation of Commercially Available Diagnostic Tests for the Detection of Dengue Virus NS1 Antigen and Anti-Dengue Virus IgM Antibody
Commercially available diagnostic test kits for detection of dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM were evaluated for their sensitivity and specificity and other performance characteristics by a diagnostic laboratory network developed by World Health Organization (WHO), the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Pediatric Dengue Vaccine Initiative (PDVI). Each network laboratory contributed characterized serum specimens for the panels used in the evaluation. Microplate enzyme-linked immunosorbent assay (ELISA) and rapid diagnostic test (RDT formats) were represented by the kits. Each ELISA was evaluated by 2 laboratories and RDTs were evaluated by at least 3 laboratories. The reference tests for IgM anti-DENV were laboratory developed assays produced by the Armed Forces Research Institute for Medical Science (AFRIMS) and the Centers for Disease Control and Prevention (CDC), and the NS1 reference test was reverse transcriptase polymerase chain reaction (RT-PCR). Results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60–75% and specificity 71–80%; NS1 RDT sensitivity was 38–71% and specificity 76–80%; the IgM anti-DENV RDTs sensitivity was 30–96%, with a specificity of 86–92%, and IgM anti-DENV ELISA sensitivity was 96–98% and specificity 78–91%. NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92-99% and the IgM anti-DENV RDTs from 88–94%. Dengue virus (DENV) infection occurs throughout tropical and sub-tropical regions of the world where dengue is a major public health problem. Laboratory diagnosis of dengue with a single serum specimen obtained during the acute phase of the illness requires tests to detect IgM antibodies to DENV or the virus genome. A previous evaluation of available tests for IgM anti-DENV showed wide variability. The present study examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable. The study found variability among the microplate ELISAs for both analytes but some tests performed with sensitivity and specificity acceptable for routine dengue diagnostics. The RDT's for both analytes had variable sensitivity that could be considered acceptable for routine clinical diagnostics. There is the need to maintain a network of dengue reference laboratories to conduct similar evaluations as additional dengue diagnostic tests become commercially available in order to guide the use for surveillance, clinical diagnosis and research.
- Top Cited Papers
- 1 December 2010
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 8 (S12) , S7-S16
Dengue: a continuing global threat
Dengue fever and dengue haemorrhagic fever are important arthropod-borne viral diseases. Each year, there are ∼50 million dengue infections and ∼500,000 individuals are hospitalized with dengue haemorrhagic fever, mainly in Southeast Asia, the Pacific and the Americas. Illness is produced by any of the four dengue virus serotypes. A global strategy aimed at increasing the capacity for surveillance and outbreak response, changing behaviours and reducing the disease burden using integrated vector management in conjunction with early and accurate diagnosis has been advocated. Antiviral drugs and vaccines that are currently under development could also make an important contribution to dengue control in the future.
- 1 December 2010
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 8 (S12) , S7-S16
Top Cited PapersDengue: a continuing global threat
Dengue fever and dengue haemorrhagic fever are important arthropod-borne viral diseases. Each year, there are ∼50 million dengue infections and ∼500,000 individuals are hospitalized with dengue haemorrhagic fever, mainly in Southeast Asia, the Pacific and the Americas. Illness is produced by any of the four dengue virus serotypes. A global strategy aimed at increasing the capacity for surveillance and outbreak response, changing behaviours and reducing the disease burden using integrated vector management in conjunction with early and accurate diagnosis has been advocated. Antiviral drugs and vaccines that are currently under development could also make an important contribution to dengue control in the future.
- Open Access
- 1 March 2009
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 15 (3) , 436-440
Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests
Anti–dengue virus immunoglobulin M kits were evaluated. Test sensitivities were 21%–99% and specificities were 77%–98% compared with reference ELISAs. False-positive results were found for patients with malaria or past dengue infections. Three ELISAs showing strong agreement with reference ELISAs will be included in the World Health Organization Bulk Procurement Scheme.
- 1 March 2009
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 15 (3) , 436-440
Open AccessEvaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests
Anti–dengue virus immunoglobulin M kits were evaluated. Test sensitivities were 21%–99% and specificities were 77%–98% compared with reference ELISAs. False-positive results were found for patients with malaria or past dengue infections. Three ELISAs showing strong agreement with reference ELISAs will be included in the World Health Organization Bulk Procurement Scheme.
- Open Access
- 1 April 2004
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 10 (4) , 719-722
Dengue 3 Epidemic, Havana, 2001
In June 2001, dengue transmission was detected in Havana, Cuba; 12,889 cases were reported. Dengue 3, the etiologic agent of the epidemic, caused the dengue hemorrhagic fever only in adults, with 78 cases and 3 deaths. After intensive vector control efforts, no new cases have been detected.
- 1 April 2004
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 10 (4) , 719-722
Open AccessDengue 3 Epidemic, Havana, 2001
In June 2001, dengue transmission was detected in Havana, Cuba; 12,889 cases were reported. Dengue 3, the etiologic agent of the epidemic, caused the dengue hemorrhagic fever only in adults, with 78 cases and 3 deaths. After intensive vector control efforts, no new cases have been detected.
- 14 May 2003
- Published by Elsevier in Journal of Virological Methods
- Vol. 110 (2) , 179-184
MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination
- 14 May 2003
- Published by Elsevier in Journal of Virological Methods
- Vol. 110 (2) , 179-184
MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination
- 1 May 1999
- Published by Elsevier in The Lancet
- Vol. 353 (9164) , 1558-1562
Urbanisation of yellow fever in Santa Cr uz, Bolivia
- 1 May 1999
- Published by Elsevier in The Lancet
- Vol. 353 (9164) , 1558-1562
Urbanisation of yellow fever in Santa Cr uz, Bolivia